Biosimilars reimbursement update

As of September 30, 2020, ^PrZiextenzo^® (pegfilgrastim) and ^PrRiximyo^®(rituximab for injection) are now eligible for reimbursement in Quebec through the RAMQ’s Public Prescription Drug Insurance Plan.

In addition, both biosimilars are on the list of medicines and establishments for use in Canadian hospitals.

As of October 7, 2020, ^PrRiximyo^® is also eligible for reimbursement in Nova Scotia through the Nova Scotia Pharmacare.

For more information on Sandoz biosimilars click here and to get evidence-based information on biosimilars in Canada visit The Biosimilars Generation web site.

Oct 19, 2020

Biosimilars reimbursement update

In addition, both biosimilars are on the list of medicines and establishments for use in Canadian hospitals.

As of October 7, 2020, ^PrRiximyo^® is also eligible for reimbursement in Nova Scotia through the Nova Scotia Pharmacare.

For more information on Sandoz biosimilars click here and to get evidence-based information on biosimilars in Canada visit The Biosimilars Generation web site.